Recent Reports

ICER’s final report on the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM, Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma/Gilead), including key policy recommendations.

View More on this Topic

Hemophilia A: Evidence Report

New England CEPAC

ICER’s review of emicizumab for treatment of hemophilia A.

View More on this Topic

This Preliminary New Evidence Update for PCSK9 inhibitor alirocumab (Praluent®, Regeneron/Sanofi) incorporates results from the ODYSSEY outcomes trial presented at the American College of Cardiology’s 2018 Scientific Session. Under ICER’s established protocols for accepting in-confidence data, an agreement with Regeneron and Sanofi allowed ICER to evaluate the new evidence and, working with a team of academic faculty from the University of California, San Francisco, to update its cost-effectiveness analyses and associated value-based price benchmarks for this drug.

Given these new outcomes data confirming a mortality benefit for alirocumab, ICER is issuing this preliminary update to help inform new pricing and coverage negotiations between manufacturers and payers. We plan to issue a final New Evidence Update for alirocumab by May 3, 2018, following the methodology and procedures defined on our website.

View More on this Topic

ICER’s Draft Evidence Report on treatments for cystic fibrosis, open to public comment from March 15 – April 12, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

Materials

Midwest CEPAC

Cystic Fibrosis: Public Comments

Midwest CEPAC

Cystic Fibrosis: Model Analysis Plan

Midwest CEPAC

Cystic Fibrosis: Research Protocol

CTAF

Migraine: Model Analysis Plan

ICER

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real World Evidence for Coverage and Formulary Decisions

ICER

Real World Evidence for Coverage Decisions: Opportunities and Challenges

CTAF

Hereditary Angioedema: Stakeholder List

CTAF

Hereditary Angioedema: Open Input

CTAF

Hereditary Angioedema: Draft Scoping Document

CTAF

CAR-T Therapies: Report-at-a-Glance

New England CEPAC

Endometriosis: Research Protocol

New England CEPAC

Endometriosis: Model Analysis Plan